-
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Study ID: ONC25053 (ALTE2131)
PI: Maggie Fader.
View Study Details
-
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Study ID: ONC99274 (AREN1921)
PI: Maggie Fader.
View Study Details
-
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Study ID: ONC25036 (AREN2231)
PI: Maggie Fader.
View Study Details
-
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Study ID: ONC25026 (ARAR2331)
PI: Maggie Fader.
View Study Details
-
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Study ID: ONC24008 (BCC016)
PI: Ossama Maher.
View Study Details
-
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Study ID: BMT23108 (ORCA-Q)
PI: Jorge Galvez-Silva.
View Study Details
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Study ID: ONC24057 (BCC021)
PI: Maggie Fader.
View Study Details
-
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)
Study ID: ONC99078 (AGCT1532)
PI: Maggie Fader.
View Study Details
-
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Study ID: ONC23174 (CONNECT1906)
PI: Ziad Khatib.
View Study Details
-
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Study ID: ONC23006 (ANHL2121)
PI: Maggie Fader.
View Study Details
-
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Study ID: ONC23127 (CONNECT2108)
PI: Ziad Khatib.
View Study Details
-
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Study ID: ONC23173 (CONNECT1905)
PI: Ziad Khatib.
View Study Details
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Study ID: ONC99101 (APAL2020SC)
PI: Maggie Fader.
View Study Details
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN)
Study ID: ONC99113 (NMTRC012)
PI: Guillermo De Angulo.
View Study Details
-
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Study ID: ONC23150 (ACCL1931)
PI: Maggie Fader.
View Study Details
-
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Study ID: ONC99271 (AHOD2131)
PI: Maggie Fader.
View Study Details
-
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Study ID: ONC99276 (ARST2032)
PI: Maggie Fader.
View Study Details
-
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) (TransIT)
Study ID: BMT23109 (TransIT)
PI: Jorge Galvez-Silva.
View Study Details
-
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Study ID: ONC25006 (ACNS2321)
PI: Ziad Khatib.
View Study Details
-
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Study ID: ONC23118 (BCC018)
PI: Maggie Fader.
View Study Details
-
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Study ID: ONC99116 (PTCTC ONC1701)
PI: Jorge Galvez-Silva.
View Study Details
-
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Study ID: ONC99270 (ACNS2031)
PI: Ziad Khatib.
View Study Details
-
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Study ID: ONC24030 (ANBL2131)
PI: Maggie Fader.
View Study Details
-
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Study ID: ONC99077 (AGCT1531)
PI: Maggie Fader.
View Study Details
-
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Study ID: ONC99085 (ANBL1531)
PI: Maggie Fader.
View Study Details
-
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Study ID: ONC99062 (AALL1732)
PI: Maggie Fader.
View Study Details
-
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Study ID: ONC99096 (AAML1831)
PI: Maggie Fader.
View Study Details
-
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Study ID: ONC99074 (ACNS1833)
PI: Ziad Khatib.
View Study Details
-
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Study ID: ONC99100 (AOST2031)
PI: Ziad Khatib.
View Study Details
-
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Study ID: ONC99099 (ACNS2021)
PI: Ziad Khatib.
View Study Details
-
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Study ID: ONC24032 (ARAR2221)
PI: Maggie Fader.
View Study Details
-
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Study ID: ONC99060 (AALL1621)
PI: Maggie Fader.
View Study Details
-
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Study ID: ONC99273 (AOST2032)
PI: Maggie Fader.
View Study Details
-
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Study ID: NEU23013 (C4951002-BHV3000-311)
PI: Wilson Heredia Nunez.
View Study Details
-
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
Study ID: NEU24071 (ION582-CS2)
PI: Paula Schleifer.
View Study Details
-
Humanitarian Device Exemption (Dystonia IRB)
Study ID: NEU99202 (H020007)
PI: Toba Niazi.
View Study Details
-
Focal Cerebral Arteriopathy Steroid Trial (FOCAS)
Study ID: NEU23170 (FOCAS)
PI: Anuj Jayakar.
View Study Details
-
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
Study ID: NEU24048 (STK-001-DS-301)
PI: Matt Lallas.
View Study Details
-
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
Study ID: NEU23134 (BT016)
PI: Toba Niazi.
View Study Details
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (EXPAND)
Study ID: NEU23003 (N01269)
PI: Anuj Jayakar.
View Study Details
-
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Study ID: NEU24088 (LP352-302)
PI: Matt Lallas.
View Study Details
-
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
Study ID: NEU24061 (LP352-301)
PI: Matt Lallas.
View Study Details
-
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Study ID: NEU24007 (EP0224)
PI: Anuj Jayakar.
View Study Details
-
A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects
Study ID: NEU99205 (BT005)
PI: John Ragheb.
View Study Details
-
A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
Study ID: NEU24062 (NGN RTT-200)
PI: Paula Schleifer.
View Study Details